Weight loss jabs like Wegovy combat several diverse conditions, from heart attacks to cancer, and the explanation may be that they stop inflammation ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, ...

Mounjaro and Wegovy are two of the biggest names in the world of weight-loss drugs but it's been unclear which is more ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

If you're considering taking a GLP-1 medication, and you also have a digestive condition, you may be wondering about side ...

What is Wegovy? What are its side effects and what does it treat? - Panorama will look at the ‘game changing’ medication but ...